NewGame+ is the world's first AI-native life extension research platform. We combine deep learning drug discovery, gene therapy optimization, and real-time biomarker analysis to push the boundaries of human longevity.
Surpassing the limits of current longevity science
From molecule to patient, our AI-powered platform covers every stage of longevity research and therapy development.
Deep learning models screen 2.4 million molecular compounds against aging-related targets. Our graph neural networks predict binding affinity, toxicity, and bioavailability simultaneously, reducing discovery timelines from years to weeks.
ActiveTransformer-based models optimize CRISPR guide RNA design, AAV vector tropism, and expression cassette architecture. We maximize on-target editing efficiency while minimizing off-target effects across the entire genome.
ActiveReal-time multi-omic biomarker analysis integrating epigenetic clocks (Horvath, GrimAge, PhenoAge), telomere length, proteomics panels, and metabolomics. Track biological age with sub-year precision across 847 biomarkers.
ActiveAdaptive trial design powered by Bayesian optimization. Our platform handles patient stratification, dose-response modeling, interim analysis, and regulatory submission prep. Reduce Phase I-III timelines by up to 40%.
BetaEvidence-based intervention stacks combining senolytics, NAD+ precursors, rapamycin analogs, metformin, and emerging therapies. Each protocol is continuously refined by reinforcement learning agents trained on outcomes data.
ResearchEvery patient gets a unique longevity blueprint built from their genomic profile, epigenetic state, microbiome composition, and lifestyle data. Our digital twin models simulate interventions before they are administered in the clinic.
BetaOur proprietary AgingClock AI integrates 12 epigenetic clock models, proteomic aging signatures, and metabolomic decay curves into a single, dynamic biological age estimate. For the first time, watch your biological age decrease in real time as interventions take effect.
Unlike static measurements, the NewGame+ AgingClock updates continuously as new biomarker data flows in, giving researchers and clinicians an unprecedented live view of the aging process and how to reverse it.
Our end-to-end pipeline takes longevity interventions from computational hypothesis to clinical reality.
AI screens millions of aging-related molecular targets, identifying the most promising pathways for intervention based on multi-omic data integration and causal inference models.
Generative chemistry models design novel molecules optimized for efficacy, selectivity, and ADMET properties. Each candidate is scored by our proprietary LongevityScore algorithm.
Digital twin simulations predict in-vivo outcomes. Organ-on-chip models accelerated by AI reduce animal testing. Biomarker panels validate mechanism of action in real time.
Adaptive trial designs powered by Bayesian optimization. Patient stratification AI ensures the right therapy reaches the right patient. Regulatory-ready data packages generated automatically.
Our active research spans senolytic drugs, gene therapies, epigenetic reprogramming, and metabolic interventions.
The greatest minds in science agree: aging is a solvable problem.
"The first person to live to 200 is probably already alive today. The question is not whether we will solve aging, but whether we will do it fast enough to matter for this generation."
"Aging is the root cause of most human suffering. Cancer, heart disease, neurodegeneration -- these are all symptoms of a single underlying process that we can now intervene in at the molecular level."
"We are not adding years to the end of life. We are extending the healthy, vibrant middle years. Imagine being biologically 30 for decades. That is the promise of longevity science done right."
Whether you are an independent researcher, clinical partner, or healthcare enterprise, there is a NewGame+ tier designed for your needs.
Join the researchers, clinicians, and visionaries who believe aging is a solvable problem. Early access members get priority when we open our platform.
Join 2,847 researchers and clinicians already on the waitlist. No spam. Unsubscribe anytime.